Hexobendine | CAS#54-03-5 | vasoactive

MedKoo Cat#: 585308 | Name: Hexobendine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Hexobendine is a potent vasoactive agent that dilates cerebral and coronary arteries, but slightly constricts femoral arteries, without any effects on heart rate, blood pressure or cardiac output.

Chemical Structure

Hexobendine

CAS#54-03-5 (free base)

Theoretical Analysis

MedKoo Cat#: 585308

Name: Hexobendine

CAS#: 54-03-5 (free base)

Chemical Formula: C30H40N2O10

Exact Mass: 588.2683

Molecular Weight: 588.65

Elemental Analysis: C, 61.21; H, 6.85; N, 4.76; O, 27.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

54-03-5 (free base) 50-62-4 (dihydrochloride)

Synonym

Hexobendine; ST 7090; ST7090; ST-7090; Ditrimin; Ditrimine; Ustimon

IUPAC/Chemical Name

Benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediylbis((methylimino)-3,1-propanediyl) ester

InChi Key

GIROHAYVVNQZLT-RYJWMXFHSA-N

InChi Code

InChI=1S/C30H40N2O10/c1-31-21(11-13-41-29(33)19-15-23(35-3)27(39-7)24(16-19)36-4)9-10-22(32-2)12-14-42-30(34)20-17-25(37-5)28(40-8)26(18-20)38-6/h15-18H,9-14H2,1-8H3/b31-21-,32-22-

SMILES Code

C/N=C(CC/C(CCOC(C1=CC(OC)=C(OC)C(OC)=C1)=O)=N/C)\CCOC(C2=CC(OC)=C(OC)C(OC)=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 588.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kolassa N, Dŏrr B, Pfleger K. [Studies on the pharmacokinetics of hexobendine in rats. I. Distribution following i.v. administration (author's transl)]. Arzneimittelforschung. 1975 Sep;25(9):1414-7. German. PubMed PMID: 1242664. 2: Kolassa N, Stengg R, Turnheim K. Influence of hexobendine, dipyridamole, dilazep, lidoflazine, inosine and purine riboside on adenosine uptake by the isolated epithelium of guinea pig jejunum. Pharmacology. 1978;16(1):54-60. PubMed PMID: 619363. 3: McInnes L, Parratt JR. Studies on the mode of action of hexobendine, a prospective anti-anginal drug. Br J Pharmacol. 1969 Sep;37(1):272-82. PubMed PMID: 5343351; PubMed Central PMCID: PMC1703777. 4: Plagemann PG, Kraupp M. Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine. Biochem Pharmacol. 1986 Aug 1;35(15):2559-67. PubMed PMID: 3741459. 5: Shibata K, Hayashi S, Toda N. [Influence of hexobendine, prenylamine and verapamil on the contractile response of isolated rabbit left atria and aortae to calcium (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Nov;73(8):931-8. Japanese. PubMed PMID: 611068. 6: Winkler R, Moser M. [Effect of hexobendine and pentoxifylline on the viscosity of erythrocyte suspension]. Wien Klin Wochenschr. 1983 Mar 18;95(6):209-13. German. PubMed PMID: 6880203. 7: Iwata H, Masukawa T, Kakuno K, Yamamoto I. [Effects of hexobendine on adenosine metabolism and myocardial energy metabolism (author's transl)]. Nihon Yakurigaku Zasshi. 1978 Oct;74(7):833-40. Japanese. PubMed PMID: 744550. 8: Rothaul AL, Broadley KJ. Use of hexobendine to examine whether the coronary vasodilator metabolite released from guinea-pig isolated hearts is adenosine. Cardiovasc Res. 1981 Oct;15(10):599-610. PubMed PMID: 7317912. 9: Diene G, Nigro P, Cottini E, Andreozzi GM, Mossuti E, Sorrentino F. [Recent contribution to the study on the effects of hexobendine in the treatment of coronary insufficiency]. Boll Soc Ital Cardiol. 1973;18(12):1213-21. Italian. PubMed PMID: 4619973. 10: Kolassa N, Pfleger K, Träm M. Species differences in action and elimination of adenosine after dipyridamole and hexobendine. Eur J Pharmacol. 1971;13(3):320-5. PubMed PMID: 5577493. 11: Kolassa N, Dörr B, Pfleger K. [Studies on the pharmacokinetics of hexobendine in rats / 2nd communication: Elimination following i.v. administration (author's transl)]. Arzneimittelforschung. 1975 Oct;25(10):1567-70. German. PubMed PMID: 1243039. 12: Hulme ME, Weston AH. Some effects of dipyridamole, hexobendine and lidoflazine on inhibitory processes in rabbit duodenum. Br J Pharmacol. 1974 Apr;50(4):609-11. PubMed PMID: 4447864; PubMed Central PMCID: PMC1776734. 13: Satchell DG, Lynch A, Bourke PM, Burnstock G. Potentiation of the effects of exogenously applied ATP and purinergic nerve stimulation on the guinea-pig taenia coli by dipyridamole and hexobendine. Eur J Pharmacol. 1972 Sep;19(3):343-50. PubMed PMID: 4344978. 14: Balcar VJ, Gundlach AL, Johnston GA. High affinity uptake of cAMP in rat brain: Inhibition by coronary vasodilators dilazep and hexobendine. Neurochem Int. 1988;12(1):19-24. PubMed PMID: 20501198. 15: Klebel VE. [Experimental psychological study of the effect of a hexobendine-etamivan-etofylline combination]. Arzneimittelforschung. 1975 May;25(5):831-6. German. PubMed PMID: 1242334. 16: Kraupp O, Niessner H, Ploszczanski B, Adler-Kastner L, Springer A, Chirikdjian JJ. A comparison of the effects of hexobendine with those of anoxia on the concentration of myocardial metabolites in vivo. Eur J Pharmacol. 1967 Mar;1(2):140-52. PubMed PMID: 6060192. 17: McHenry LC Jr, Jaffe ME, Kawamura J, Goldberg HI. The effect of Hexobendine on regional cerebral blood flow in stroke patients. Neurology. 1970 Apr;20(4):375. PubMed PMID: 5534978. 18: Zimmermann W. [Clinical experience with N,N'-dimethyl-N,N'-bis-(3-(3',4',5'-trimethoxybenzoyloxy)-propyl)-ethylenediamine dihydrochloride (hexobendine)]. Arzneimittelforschung. 1968 Aug;18(8):1112-4. German. PubMed PMID: 5756048. 19: Turnheim K, Plank B, Kolassa N. Inhibition of adenosine uptake in human erythrocytes by adenosine-5'-carboxamides, xylosyladenine, dipyridamole, hexobendine, and p-nitrobenzylthioguanosine. Biochem Pharmacol. 1978;27(18):2191-7. PubMed PMID: 728171. 20: Cook P, James I. Drug therapy: cerebral vasodilators (first of two parts). N Engl J Med. 1981 Dec 17;305(25):1508-13. Review. PubMed PMID: 7029283.